- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05527041
A Highly Portable Device for Assessment of Mild Traumatic Brain Injury in Deployed and Far-Forward Settings
The purpose of this study is to develop a highly portable, ruggedized diagnostic tool for concussion, EyeBOX Lens (EBLens), that can be utilized in deployed field and far-forward settings. The EBLens will be based on a concussion diagnostic algorithm from the FDA cleared EyeBOX device, developed by Oculogica, and eye-tracking data collected from a wearable set of eye-tracking glasses, developed by Adhawk Microsystems. Once the EBLens is prototyped, an algorithm for diagnosing concussion will be developed that is specifically appropriate for the EBLens via a case-control clinical study comparing 100 concussed to 100 non-concussed subjects (Phase I). Participants, age 18-35 years, will be recruited from the KACH research team and affiliated providers and clinical sites. Concussed individuals will be assessed within 72 hours of concussion. Demographics, basic medical history, symptom severity, a visio-vestibular exam and the EBLens scan will be collected on both injured cases and uninjured controls at a single time point.
The algorithm and the EBLens will be validated in a subsequent, prospective cohort validation study (Phase II) designed for FDA submission. The correlation of the EBLens output with resolution of symptoms will also be observed in longitudinal follow-up of concussed participants in the validation study. The participant population for this study will be cadets recruited from the USMA and young athletes recruited from affiliated sites during baseline concussion testing. Participants will be assessed at baseline at the start of their academic year or sports season. Those participants who experience a concussive injury will be assessed again at three time points; 1) within 72 hours of injury, 2) weekly until and at the time of initiation of a graded return to activity protocol, and 3) upon clearance for unrestricted RTP/RTD.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Rosina Samadani, PhD
- Phone Number: 484-393-2694
- Email: rosina@oculogica.com
Study Contact Backup
- Name: Viridiana Juarez
- Email: viridiana@oculogica.com
Study Locations
-
-
New York
-
West Point, New York, United States, 10996
- Keller Army Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
CONCUSSED:
Inclusion Criteria:
- Provide documented informed consent.
- Have presented, at any time post injury, for any complaint related to an injury involving either a direct force to the head or a blow to the body that has the potential to transmit a rapid acceleration/deceleration of the head, with or without loss of consciousness, with or without external signs of head injury.
- Be a current cadet/enrolled student age 17-34.
- Have the ability to provide a complete ophthalmologic, medical, and neurologic history as well as report current medications.
Exclusion Criteria:
- Have penetrating trauma or known skull fracture or intracranial injury.
- Have had a conventional head CT or MRI demonstrating evidence of structural brain injury (subdural, epidural or intraparenchymal hemorrhage, edema/mass effect per attending radiologist read).
- Be blind (no light perception), have missing or non-functional eyes.
- Be unable to open their eyes.
- Have a history of unresolved strabismus, diplopia, amblyopia.
- Have a history of unresolved cranial nerve III, IV, or VI palsy.
- Have a history of unresolved macular edema, retinal degeneration, extensive cataract, or ocular globe disruption.
- Have a history of extensive prior eye surgery or scarring (examples include strabismus surgery, scleral buckle repair of retinal detachment, repair of blow out fractures of the orbit and any procedures that would interfere with extraocular muscle movements; prior cataract surgery or Lasik are not exclusions).
- Have a prior history of unresolved ocular-motor dysfunctions.
- Be intoxicated.
CONTROLS:
Inclusion Criteria:
- Provide documented informed consent.
- Be a current cadet/enrolled student age 17-34.
- Have the ability to provide a complete ophthalmologic, medical, and neurologic history as well as report current medications.
Exclusion Criteria:
- Have presented, within the prior six months, for any complaint related to an injury involving either a direct force to the head or a blow to the body that has the potential to transmit a rapid acceleration/deceleration of the head, with or without loss of consciousness, with or without external signs of head injury.
- Have penetrating trauma or known skull fracture or intracranial injury.
- Have had a conventional head CT or MRI demonstrating evidence of structural brain injury (subdural, epidural or intraparenchymal hemorrhage, edema/mass effect per attending radiologist read).
- Be blind (no light perception), have missing or non-functional eyes.
- Be unable to open their eyes.
- Have a history of unresolved strabismus, diplopia, amblyopia.
- Have a history of unresolved cranial nerve III, IV, or VI palsy.
- Have a history of unresolved macular edema, retinal degeneration, extensive cataract, or ocular globe disruption.
- Have a history of extensive prior eye surgery or scarring (examples include strabismus surgery, scleral buckle repair of retinal detachment, repair of blow out fractures of the orbit and any procedures that would interfere with extraocular muscle movements; prior cataract surgery or Lasik are not exclusions).
- Have a prior history of unresolved ocular-motor dysfunctions.
- Be intoxicated.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Concussed
Subjects age 17-34 years within 72 hours of injury.
|
The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:
|
Non-concussed
In Phase I, uninjured, matched controls.
In Phase II, subjects completing baseline concussion testing as part of the standard of care or athletics pre-season.
|
The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic accuracy of acute clinical diagnosis of concussion using EBLens form factor and algorithm
Time Frame: Within 72 hours of injury
|
The EBLens will have at least 70% sensitivity and specificity for diagnosis of acute concussion
|
Within 72 hours of injury
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic accuracy of recovery determination for return to activity and duty (RTA / RTD) using EBLens form factor and algorithm
Time Frame: Through study completion, up to one year
|
The EBLens will have at least 70% sensitivity and specificity for recovery determination for return to activity and duty (RTA / RTD) without complication.
|
Through study completion, up to one year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kenneth Cameron, PhD, Keller Army Community Hospital
- Principal Investigator: Sadie Buboltz-Dubs, PhD, University of Wisconsin - Green Bay
- Principal Investigator: Christina Master, MD, Children's Hospital of Philadelphia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- W81XWH21C0103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Traumatic Brain Injury
-
McGill University Health Centre/Research Institute...UnknownMild Traumatic Brain Injury; ConcussionCanada, France, Israel
-
ElMindA LtdGE HealthcareCompletedTBI (Traumatic Brain Injury) | Mild Traumatic Brain Injury | Concussion, MildUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityHealth Science Center of Xi'an Jiaotong University; The Second Affiliated Hospital...RecruitingMTBI - Mild Traumatic Brain InjuryChina
-
Perception Dynamics InstituteUniversity of California, San Diego; University of South Alabama; University...RecruitingMTBI - Mild Traumatic Brain InjuryUnited States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted
-
Washington University School of MedicineTerminated
-
Centre Hospitalier de DouaiCompletedCompliance, Patient | Mild Brain Traumatic InjuryFrance
-
Bispebjerg HospitalUniversity of Copenhagen; Synoptik-Fonden; IT University of Copenhagen; The Danish...RecruitingBrain Concussion | mTBI - Mild Traumatic Brain InjuryDenmark
-
Children's National Research InstituteCreare, Inc.RecruitingConcussion | MTBI - Mild Traumatic Brain InjuryUnited States
-
University of CopenhagenRigshospitalet, Denmark; Sygekassernes HelsefondCompletedMild Traumatic Brain Injury | Concussion, MildDenmark
Clinical Trials on EyeBOX Lens (EBLens)
-
Oculogica, Inc.CompletedImpairment | Cannabis IntoxicationUnited States
-
Oculogica, Inc.CompletedIntracranial Pressure IncreaseUnited States
-
Oculogica, Inc.Completed
-
Oculogica, Inc.CompletedBrain Injuries | Craniocerebral Trauma | Trauma, Nervous System | Brain Concussion | Concussion, Mild | Concussion, Severe | Concussion, Intermediate | Cerebral ConcussionUnited States
-
Oculogica, Inc.CompletedMild Traumatic Brain Injury | Concussion, BrainUnited States
-
Walter Reed National Military Medical CenterUnited States Department of Defense; Oculogica, Inc.; Sync-Think, Inc.; Neurolign; TBIC...Completed
-
Coopervision, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Coopervision, Inc.Completed
-
Coopervision, Inc.Completed